Protocol H8H- MC-LAHT(c)  
Safety, Tolerability, and Pharmacokinetics of Lasmiditan when Co- administered with 
Topiramate in Healthy  Subjects  
 
[STUDY_ID_REMOVED] 
Approval Date: 20- Oct-2017 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 1
LY573144Protocol H8H -MC-LAHT(c)
Safety , Tolerability , and Pharmacokinetics of Lasmiditan 
when Co -administered with Topiramate in Healthy  
Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
lasmiditan (LY573144 ), unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commerciall y confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Lasmiditan (LY573144)
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Sign ed and Approved by Lilly: 
03 August 2017
Amendm ent (a) Electronical ly Signed and Approved by Lilly: 05 September 2017
Amendm ent (b) Electronical ly Signed and Approved by Lilly: 11 October 2017
Amendm ent (c) Electronical ly Signed and Approved by Lilly on approval date provided 
below.
Approval Date: 20-Oct-2017 GMT
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 2
LY573144Table of Contents
Safety , Tolerability , and Pharmacokinetics of Lasmiditan 
when Co -administered with Topiramate in Healthy  Subjects
Section Page
Protoco l H8H -MC-LAHT(c) Safet y, Tolerabilit y, and Pharmacokinetics of 
Lasmiditan when Co -administered with Topiramate in Healthy 
Subjects .............................................................................................................................. 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 8
2. Schedule of Act ivities....................................................................................................... 10
3. Introduction ...................................................................................................................... 16
3.1. Study  Rati onale ............................................................................................................ 16
3.2. Background .................................................................................................................. 16
3.3. Benefit /Risk Assessment .............................................................................................. 17
4. Object ives and Endpo ints.................................................................................................. 18
5. Study  Design ..................................................................................................................... 19
5.1. Overall Design ............................................................................................................. 19
5.2. Num ber of Participants .................................................................................................20
5.3. End of Study  Definit ion............................................................................................... 20
5.4. Scientific Rationale for Study  Design ........................................................................... 20
5.5. Justification for Dose ................................................................................................... 21
6. Study  Popul ation............................................................................................................... 22
6.1. Inclusio n Cri teria.......................................................................................................... 22
6.2. Exclusio n Cri teria........................................................................................................ 23
6.2.1. Rationale for Excl usion of Certain Study  Candidates ........................................... 24
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 25
6.3.1. Meals and Dietary  Restri ctions............................................................................. 25
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 25
6.3.3. Activity................................................................................................................ 25
6.4. Screen Failures ............................................................................................................. 25
7. Treat ment .......................................................................................................................... 26
7.1. Treatment Administered ............................................................................................... 26
7.1.1. Packaging and Labeling ....................................................................................... 27
7.2. Method of Treatment Assignment ................................................................................ 27
7.2.1. Selection and Timing o f Doses ............................................................................. 27
7.3. Blinding ....................................................................................................................... 27
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 3
LY5731447.4. Dose Modificat ion........................................................................................................ 27
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 28
7.6. Treatment Compliance .................................................................................................28
7.7. Concomitant Therapy ................................................................................................... 28
7.8. Treatment after the End of the Study ............................................................................ 28
8. Discontinuati on Cri teria .................................................................................................... 29
8.1. Discontinuati on from Study  Treatm ent......................................................................... 29
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 29
8.2. Discontinuati on from the Study .................................................................................... 29
8.3. Subjects Lost to Follow -up........................................................................................... 30
9. Study  Assessments and Procedures ................................................................................... 31
9.1. Efficacy Assessments ................................................................................................... 31
9.2. Adverse Events ............................................................................................................ 31
9.2.1. Serious Adverse Events ........................................................................................ 32
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 32
9.2.2. Com plaint Handling ............................................................................................. 33
9.3. Treatment of Overdose .................................................................................................33
9.3.1. Overdose of Lasmiditan ....................................................................................... 33
9.3.2. Overdose of Topiramate ....................................................................................... 33
9.4. Safety........................................................................................................................... 33
9.4.1. Laboratory  Tests .................................................................................................. 33
9.4.2. Vital Signs ........................................................................................................... 33
9.4.3. Electrocardi ogram s.............................................................................................. 34
9.4.4. Columbia Suici de Severi ty Rating Scal e............................................................... 34
9.4.5. Neurol ogical Examinat ions.................................................................................. 35
9.4.6. Safety Moni toring ................................................................................................ 35
9.4.6.1. Hepati c Safet y................................................................................................ 35
9.5. Pharmacokinet ics......................................................................................................... 36
9.5.1. Bioanalysis ........................................................................................................... 36
9.6. Pharm acodynamics ...................................................................................................... 36
9.7. Genet ics....................................................................................................................... 36
9.8. Biomarkers ................................................................................................................... 37
9.9. Heal th Economics ........................................................................................................ 37
10. Statistical Considerations and Data Analysis ..................................................................... 38
10.1. Sample Si ze Determinat ion.......................................................................................... 38
10.2. Popul ations for Analyses .............................................................................................. 38
10.2.1. Study  Parti cipant Disposit ion............................................................................... 38
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 38
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 4
LY57314410.3. Statistical Analyses ...................................................................................................... 38
10.3.1. Safety Analyses .................................................................................................... 38
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 38
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 39
10.3.2. Pharmacokinet ic Analyses .................................................................................... 39
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 39
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 39
11. References ........................................................................................................................ 40
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 5
LY573144List of Tables
Table Page
Table LAHT.1. Object ives and Endpo ints....................................................................... 18
Table LAHT.2. Treatments Administered ........................................................................ 26
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 6
LY573144List of Figures
Figure Page
Figure LAHT.1. Illustrati onof study  design for Protocol H8H -MC-LAHT. ...................... 20
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 7
LY573144List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 41
Appendix 2. Clinical Laboratory  Tests ........................................................................ 45
Appendix 3. Study  Governance, Regulatory , and Ethi cal Considerati ons.................... 46
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 49
Appendix 5. Blood Sam pling Summary ...................................................................... 50
Appendix 6. Neurol ogical Examinat ions..................................................................... 51
Appendix 7. Protocol  Amendment H8H -MC-LAHT(c)  Summary  Safety, 
Tolerabilit y, and P harm acokinetics of Lasmiditan when Co -
administered with Topiramate in Healt hy Subjects .................................53
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 8
LY5731441.Protocol Synopsis
Title of Study:
Safety, Tolerability, and Pharma cokinetics of Lasmiditan when Co -administered with Topiramate in Healthy 
Subjects
Rationale: 
Topiramate is indicated for prophylaxis of migraine and may be used concomitantly with lasmiditan in the intended
patient population.  Study H8H-MC -LAHT ( LAHT )is being conducted to evaluate the safety ,tolerability ,and 
pharmacokinetics ( PK)of lasmiditan when co -administered with topiramate in healthy subjects.
Objective(s)/Endpoints:
Objectives Endpoints
Primary
Toevaluate the safety and tol erability  of 
a single dose of l asmiditan in 
combinatio n with topiramate in healthy 
subjects.A summary of the number of treatment -emergent 
adverse events and serious adverse events .
Secondary
To evaluate the PK of lasmiditan alone 
andin combination with topiramate in 
healthy  subjects.
To evaluate the PK of topiramate alone 
and in combination with lasmiditan .Maximum observed drug concentration (Cmax), time of 
Cmax(tmax), area under the concentration versus time 
curve from zero to last, and zero to infinity
Cmax, tmax, and area under the concentration versus time 
curve during 1dosing interval
Summary of Study Design :  
Study LAHT i s a parallel , placebo -controlled, fixed -sequence study that assesses the safety, tolerability, and 
potential for PK interaction between investigator -and subject -blind lasmiditan /placebo and open -label topiramate.
A single dose of lasmiditan (200 mg) or placebo will be administered on the morning of Day 1. Topiramate 25 mg 
once daily (Day 3), 25 mg twice daily ( BID)(Day s 4to 7),50mg BID (Day s 8to 13), followed by a single 50-mg 
dose on the morning of Day 14will be administered . A single dose of lasmiditan (200 mg) or placebo will be 
co-administered with topiramate (50mg)on the morning of Day 14.
Treatment Arms and Planned Duration for Subjects :
  
Screening Period: All subjects will participate in a screening visit of up to 28 days.  
Treatment period: The subjects will be admitted to the clinical research unit (CRU) on the day before dosing 
(Day  -1).  Subjects will be discharged from CRU on Day 16 when all study procedures have been completed.
Follow -up period: Subjects will be discharged from the stud y approximately  10 day s after the last dose of 
topiramate.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 9
LY573144Number of subjects :
Approximately 30subjects may be enrolled so that at least 21complete the study.
Statistical Analysis:
Safety parameters that will be assessed include safety laborator y param eters, vital signs, neuro logical exam ination , 
Columbia Suicide Severity Rating Scale , and 12-lead electrocardiogram parameters.  The parameters will be listed, 
and summarized using standard descriptive statistics , as appropriate .  
Pharmacokinetic paramete r estimates for lasmiditan ,its metabolites ,and topiramate will be calculated using
standard no ncompartmental methods of analysis.   
The parameters will be listed, and summarized using standard 
descriptive statistics , as appropriate .
Pharmacokinetic parameters will be evaluated to determine the impact of topiramate co -administration on the PK of 
a single dose of lasmiditan and its metabolites .  Log -transformed C maxand area under the concentration versus time 
curve parameters will be evaluated in a li near mixed-effects model with fixed effects for treatment (lasmiditan co -
administered with topiramate [Day 14; test treatment] versus lasmiditan alone [Day 1; reference treatment]), and a 
random effect for subject.  The treatment differences will be back -transformed to present the ratios of geometric 
means and the corresponding 90% confidence interval (CI).
A similar analysis will be performed to determine the impact of co -administratio n of a single dose of lasmiditan on 
the steady -state PK of topiramate.  The model will include the following treatments:  topiramate co -administered 
with lasmiditan (Day 14; test treatment) versus topiramate alone (Day 13; reference treatment).
The t maxwill be analyzed using the Wilcoxon signed rank test.  Estimates of the median difference based on the 
observed medians, 90% CIs, and p -values from the Wilcoxon test will be calculated.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 10
LY5731442.Schedule of A ctivities
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 11
LY573144Study Schedule Protocol H8H -MC-LAHT
Screening Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~10 
days 
after 
last 
dose
Informed Consent X
Subject Admission 
to CRUX
Subject Discharge 
from CRUX
Lasmiditan/Placebo 
AdministrationX
Day 1, 
indicates 
Time = 
0X
Topiramate 
Administration
X X X X X X X X X X X X25 mg QD on 
Day 3, 25 mg 
BID from Day 4 
to 7, 50 mg BID 
from Day 8 to 
13, a single 50 -
mg dose on the 
morning of Day 
14
Neuro logical
Exam ination
X X X X X X X XOn dosing days, 
alltime points
predose and 4 -
hour postdose
for morning 
dose only.  Day 
3 is predose 
only. Non -
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 12
LY573144Screening Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~10 
days 
after 
last 
dose
dosing days at 
single time 
point. 
C-SSRS /Self -Harm X X X X
Medical History X
Height X
Weight
X X XBody weight 
should be 
recorded on Day 
-1 of all study 
periods.  
Vital Signs 
(supine)
X X0,2, 4, 
8 h24
h0 & 2 h0 
& 
2
h0 
& 
2
h0, 2, 4, 
8 h0, 2, 4, 
8 h24h X XOn dosing days, 
time points 
correspond to 
morning dose 
only.  Day 3 
time points at 
evening dose.
Time points 
may be added 
for each study 
period, if 
warranted and 
agreed upon 
between Lilly 
and the 
investigator.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 13
LY573144Screening Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~10 
days 
after 
last 
dose
Triplicate BP 
monitoring
Orthostatic Blood 
Pressure
X0, 2, & 4 
h0, 2, & 
4 h0, 2, & 
4 hDay 13 time 
points at 
morning dose 
only.
Clinical Lab oratory
Tests
X X X X XSee Appendix 2 , 
Clinical 
Laboratory 
Tests, for 
details.
Pregnancy Test 
X X XSerum 
pregnancy test 
will be 
performed at 
screening.  
Urine 
pregnancy test 
will be 
performed at 
every admission 
period and at 
poststudy, if 
applicable.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 14
LY573144Screening Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~10 
days 
after 
last 
dose
Physical 
Exam inationX X Predose X After screening, 
medical 
assessment is 
performed  only 
to include 
medical review 
and targeted 
examination, as 
appropriate.
12-L ead ECG X Predose X X X X X X Single ; all at 
predose for 
morning dose 
only.
AE/Medication 
ReviewX X X X X X X X X X X X X X X X X X
Lasmiditan and 
Metabolite PK 
SamplesPredose, 
0.5, 1, 
1.5, 2, 3, 
4, 6, 8, 
12h24, 
36
h48hPredose, 
0.5, 1, 
1.5, 2, 
2.5, 3, 
4, 6, 8, 
12h24, 
36h48h
Topiramate PK 
SamplesPredose, 
0.5, 1, 
1.5, 2, 
3, 4, 6, 
8, 12 hPredose, 
0.5, 1, 
1.5, 2, 
3, 4, 6, 
8, 12 hTime points at 
morning dose 
only.
Genetic Sample X
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 15
LY573144Abbreviations: BID = twice daily; BP= blood pressure; CRU = clinical research unit; C-SSRS = Columbia Suicide Severity Rating Scale ;ECG = electrocardiogram ; ED = early discontinuation ; h = 
hour; min = minutes; PK = pharmacokinetics ; QD = once daily . 
Note:  if multiple procedures take place at the same time point, the following order of the procedure should be use d: ECG, vital signs, and venipuncture.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 16
LY5731443.Introduction
3.1. Study Rationale
Lasmiditan is a small mo lecule serotonin (5 -hydroxytryptamine 1F)receptor agonist being 
developed for the acute treatment of migraine.
Topi ramatetaken daily  is indicated for prophylaxis of migraine and may be used conco mitantly
with lasmidi tanin the intended patient populat ion. As such, it is important to understand 
potenti al interact ions between drugs commo nly used in treating migraine, specifically, whether 
co-administration of such agents results in an increased safet y risk or any change in the exposure 
toeither (or both). Very  comm on adverse events (AEs) (≥1/10) associated with topiramate 
include dizziness, somno lence, paresthesia, nausea ,and fatigue (Topi ramate US Prescribing 
Inform ation [https://www.topamax.com/files/topamax. pdf]).  Given the occurren ce of similar 
AEs observed fo llowing administration of single doses of lasmiditan as documented in 
Secti on3.2, it is important to understand the tolerabilit y when both are co -administered.
Topi ramate is not extensively  metabo lized and is primarily eliminated unchanged in the urine .  
Six metabolites have been ident ified in humans, none of which const itutes m ore than 5% of an 
administered dose.  The metabo lites are form ed via hydroxylat ion, hydro lysis, and 
glucuronidat ion.  In vitro studies indicate that topiramate does not inhibit enzyme activit y for 
cytochrom e P450 (CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5 
isozymes.  In vitro studies indicate that topiramate is a mild inhibitor of CYP2C19 and a mild 
inducer of CYP3A4 (Topi ramate US Prescribing Informat ion 
[https://www.topamax.co m/files/topam ax.pdf]) . 
Following exploratory  analysis of human plasma samples from adult subjects receiving oral 
lasmidit an, 3 m ajor human metabolites (M7, M8, and [S,R]- M18) were observed.  Ketone 
reducti on of  lasmidi tan to M8 (al coho l) appears to be the maj or m etabolic pathway, presumably
vianon-CYP enzymes.  In human liver microsomes, CYP1A2 and CYP3A4 appear to be 
involved to a minor extent in lasmiditan metabo lism.  Unchanged lasmiditan comprises 
approximately  2% of  the dose excreted in urine.  Lasmidita n is a very  weak inhibitor of 
CYP3A4, CYP2D6, and P -glycoprotei n.
Although the probabilit y of a pharmacokinet ic (PK) drug-drug i nteracti on between lasmiditan 
and topi ramate is considered very  low based on the l ow inhibitory  potenti al of both drugs and 
their diverse eliminat ion pathways, a study  of their PK interaction is being conducted as a 
secondary  endpoint to the safet y and tol erabili ty of both drugs because of the likelihood for 
concomitant use in clinical pract ice.
3.2. Background
Across the completed Phase 1, 2, and 3 clinical studies, doses of 0.1 to 400 mg of lasmiditan 
were evaluated in healt hy subjects or patients with migraine.  To date, lasmiditan has been 
administered to 2 30healthy subjects and to 1632 patients with migraine.  Com pared wi th 
placebo, the m ost frequent ly reported lasmiditan treatment -emergent adverse events (TEAEs) 
included dizziness, paresthesia, somno lence, fatigue, lethargy , and nausea . The majo rity of these 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 17
LY573144TEAEs were mild or moderate in sev erity and none l ed to subj ect wi thdrawal .  One patient 
experienced a serious adverse event (SAE) of dizziness that was moderate in severit y (lasmidi tan 
200 m g).
Oral tablet doses of lasmiditan up to 400 mg did not result in any clinically relev ant changes in 
electrocardi ogram s (ECGs) (including QT interval/corrected QT interval [QTc]) following 
administration to healthy  subjects. In the thorough QT study in healthy subjects, no clinically  
significant changes in bl ood pressure, heart rate, or 12 -lead ECG were observed at the 100- or 
400-mg single -dose l evels .  Lasmidi tan caused no si gnificant QT prol ongat ion at ei ther dose.
In healthy subjects, peak plasma concentrations of lasmiditan were observed appr oximately 1 to 
2.5 hours after a single oral dose ranging fro m 25 to 400 m g, and the geometric mean terminal 
half-life was approximately 4 to 6 hours.  Lasmidit an exhibited dose -linear PK; low to moderate 
intersubject variabilit y in exposure was observed a cross doses (%coefficient of variat ionup to 
61% and 45% for maximum observed drug concentration [Cmax] and area under the concentration 
versus time curve [AUC], respectively ).  Co-administration of lasmiditan with a high -fatdiet led 
to a delay in median t ime of maximum observed drug concentration (t max) value by  
approximately  1 hour and a m odest (~20%) increase in lasmiditan C maxand AUC values, relat ive 
to that under fasted condit ions.
3.3. Benefit/Risk Assessment
The primary  object ive o f this study  is to eval uate the safet y and tol erabili ty of a single dose of 
lasmiditan in co mbinat ion with topiramate in healt hy subjects. There i s no anti cipated 
therapeuti c benefit for the subjects.
No clinically  significant safet y or tol erabilit y conce rns have been identified in subjects to date 
for lasmidi tan up to the highest single oral dose given (400 mg).  Dosing of lasmiditan in this 
study  will be conducted in an inpat ient setting, and subjects will be monitored in the clinical 
research unit (CRU )for at least 48 hours after dosing.
More informat ion about the known and expected benefits, risks, SAEs ,and reasonably 
anticipated AEs of lasmiditan isto be found in the Invest igator’s Brochure (IB).  
Topi ramate is a marketed drug and will be administe red within a dose titration regimen that has 
been tol erated in previous PK studi es in heal thy subjects ( e.g. Bi aler et al. 2013 ;Mani tpisitkul 
etal. 2014a,b).
More detailed informat ion about the known and expected benefits and risks of topiramate may be 
found in the fo llowing:  2017 US Prescribing Informat ion.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 18
LY5731444.Objectives and Endpoints
Table LAHT .1shows the object ives and endpo ints of the study .
Table LAHT.1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the safety and tolerability of a single dose 
of lasmiditan in combination with topiramate in healthy 
subjects. A summary of the number of treatment -emergent 
adverse events and serious adverse events
Secondary
To evaluate the pharmacokinetics of lasmiditan alone 
and in combination with topiramate in healthy subjects.
To evaluate the pharmacokinetics of topiramate alone 
and in combination with lasmiditan .Cmax, tmax, AUC(0 -tlast) and AUC(0 -∞)
Cmax, tmax, and AUC 
Exploratory
To evaluate the pharmacokinetics of lasmiditan 
metabolites alone and in combination with topiramate 
in healthy  subjects.Cmax, tmax, AUC(0 -tlast) ,and AUC(0 -∞)
Abbreviations:  AUC(0 -tlast) = area under the concentration versus time curve from time zero to time t, where t is 
the last time point with a measurable concentration; AUC(0 -∞)= area under the concentration versus time curve
from zero to infinity; AUC= area under the concentration versus time curve during 1 dosing interval; Cmax= 
maximum observed drug concentration ; tmax= time to Cmax.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 19
LY5731445.Study  Design
5.1. OverallDesign
This is a Pha se 1,parallel, placebo -controlled, fixed -sequence study  with open -label 
administration of topiramate and invest igator -and subject -blind administration of 
lasmiditan /placebo conducted in healthy subjects.
Subjects will be admitted to the CRU on Day  -1 and are expected to remain a resident until all 
assessments are completed on Day  16;however ,subjects m ay be allowed to leave the CRU at 
the discret ion of the invest igator. 
Study  governance considerations are described in detail in Appendix 3 .
Lasmiditan and topiramate doses will be administered at the CRU. Subjects will be rando mly 
assigned in a 2:1 ratio to receive lasmiditan or placebo on both lasmiditan dosing days (Days 1 
and 14).  A single oral dose of study  drug (200-mglasmiditan or placebo) will  be administered in 
the morning on Day  1. After lasmiditan wash -out, t opiramate will be titrated up to 100mg on 
Days 3 to 13. On Day 14, 1 oraldose of l asmidi tan 200 m gor placebo will be co -administered
with the final topiramate dose (50 m g) in the morning.
Blood sam pling for PK assessment will be conducted predose and at time points up to 48 hours 
postdose on Day s1 and 14for the measurement of plasma conce ntrations of lasmiditan and i
ts 
metabo lites.  Bloodsamples will also be colle cted predose and up to 12 hours p ostdose on Day s 
13and 14for the m easurement of plasma concentrations o f topiramate .
A follow-up visit will take place at least 10 days following co -administration of lasmiditan and 
topiramate (Day  14).
Figure LAHT .1illustrates the study  design.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 20
LY573144Abbreviations: LY = lasmiditan (200 mg); n = number of subjects in each group ; P = 
placebo.
Symbols: “25” inside a circle = one 25-mg tablet of topiramate ; gray pentagon =
lasmiditan dose or placebo .
Figure LAHT.1 . Illustration of study design for Protocol H8H-MC-LAHT.
5.2. Number of Participants
Approximately  30 subjects may be enrolled sothat at least 21 subjects complete the study .  For 
purposes of this study , a subject completes the study when all scheduled procedures shown in the 
Schedule of Act ivities have been finished.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on
 2) for the last subject .
5.4. Scientific Rationale for Study Design
Subjects will be rando mly assigned to 1 of 2 treatment arms.  Treatment arms run in parallel and 
both receive the same topiramate dosing schedule. One treatment arm will receive lasmiditan 
(200 m g) on Day s 1 and 14 when the other receives a lasmiditan placeb o to control  for observed 
AEs.
The study  has a doubl e-blind (subject -and invest igator-blind), fixed -sequence design in which 
each subject receives lasmiditan or placebo alone, topiramate alone, and lasmiditan or placebo 
co-administered with topiramate, allowing each subject to act as his/her own control for safet y 
and PK comparisons. A single 200 -mg dose of lasmiditan was select ed as i t is the highest 

H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 21
LY573144potenti al recommended dose for l asmidi tan.  The washout peri od between l asmidi tan doses of 
14days is considered sufficient based on the half -life of lasmiditan of approximately 4 to 
6hours. Topiramate will  be administered using a titration schedule over a period of 12 days to 
aid tolerabilit y, with a single dose of lasmiditan or placebo co -administered on the final day, to 
ensure that topiramate concentrations are at steady state at the time of lasmiditan or placebo 
dosing .
5.5. Justif ication for Dose
The dose level o f 200-mg lasmiditan has been well tolerated in previous studies of healt hy 
subjects; 200 mg is expected to be the highest recommended single dose of lasmiditan. 
As described in the label, topiramate is initiated at 25 mg/day (Day  3), increased to 50 mg/day 
(Day s 4to 7),and maintained at 100 mg/day (Days 8 to 13).Therecommended dosage for 
migraine prophylaxis is 100 mg/day (Topiramate US Prescribing Information 
[https://www.topamax.co m/files/topam ax.pdf])
. Similar topiramate titration schedules to reach
steady state in healt hy subjects demonstrate acceptable safet y profiles ( Bialer et al . 2013 ; 
Mani tpisitkul et al . 2014a ) and are generally well tolerated ( Manitpisitkul et al. 2014b).
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 22
LY5731446.Study  Population
Eligibilit y of subjects for the study  will be based on the results of screening medical history , 
physical examinat ion, vital signs, clinical laboratory tests ,and ECG. 
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occur up to 28 day sprior to enrollment.  Subjects who are not enrolled within 
28daysof screening may  be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the following criteria at 
screening :
[1] are overtly healt hy males or females, as determined by  medical history  and 
physical examinat ion.
[1a]male subjects:
are not required to adhere to con tracepti ve requi rements . 
[1b] female subjects:
ofnon-childbeari ng potenti al, i.e.,postmenopausal or permanent ly sterile 
following hysterectomy, bilateral salpingectomy ,or confirmed tubal 
occlusion (not tubal  ligation),as determined by written or spoken medical 
history .  Postm enopausal  is defined as spontan eous am enorrhea for at least 
12months, and a plasma fo llicle -stimulating hormone level greater than 
40mIU/mL, unless the subject is taking hormone replacement therapy  
(HRT). 
[2] are a ged18 to 65 years at the time of screening. 
[3] have a body  mass index (BMI) of 19.0 to 35.0 kg/m 2, inclu sive, at the time of 
screening.
[4] h ave clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igativesite, or resul ts wi th acceptabl e deviat ions that are 
judged to be not clinically signifi cant by  the investigator .
[
5] have venous access sufficient to allow for blood sampling as per the protocol .
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures .
[
7]have given written informed consent approved by  Lilly and the ethi cal review 
board (ERB) governing the site.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 23
LY5731446.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[8] are CRU personnel directly affiliated with this study and their immediate 
families.  Immediate family is defined as a spouse, bio logical or legal 
guardi an, child, or sibling.
[
9]are Lilly  or Covance empl oyees.
[10]are currently enrolled in a clinical  study  involving an invest igational product 
(IP) or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study.
[11] have known allergies to lasmiditan , topi ramate , related compounds or any  
components of the formula tion of  lasmidi tan or topiramate.
[12]are persons who have previously received th e IPin this study , withdrawn fro m 
this study ,or received lasmiditan in any other study  invest igating lasmidi tan.
[13] have participated (dosed with IP [lasmidi tan or pl acebo]), within the past
30days, in a clinical study  involving an IP.  If the previous IPhas a long 
half-life, 5 half -lives or 30 days (whichever i s longer) shoul d have passed.
[
14] have a history  of, or ECG findings of, clinically significant brady cardia, heart 
block, tachy  or brady  arrhy thmias, or have an y other abnormalit y in the 
12-lead ECG that, in the opinio n of the invest igator, increases the risks 
associ ated wi th parti cipat ingin the study . 
[15] have an abnormal supine blood pressure, defined as systolic blood pressure 
<90 or >140 mmHg or diastolic blood pressure <60 or >90 mmHg at 
screening.  Repeat assessment smay be perform ed to confirm eligibilit y.
[
16] ha ve a significant history  of or current card iovascular, respiratory (including 
bronchospasm or bronchial asthma, or chronic obstructive airways disease) , 
hepat ic, renal, gastrointest inal, endocrine, hematological, or neurological 
disorders capable o f significant ly altering the absorpti on, m etabolism , or 
eliminat ion of drugs; of constituting a risk when taking the study  medicat ion; 
or of interfering wit h the interpretation of data .  Appendectomy, splenectomy, 
and cho lecystectomy are considered as acceptable.
[
17] show a histo ry of central  nervous sy stem  (CNS) condit ions such as strokes, 
transi ent ischemic attacks, significant head trauma, CNS infect ions, migraines, 
brain surgery ,or any  other neurol ogical condi tions that, in the opinio n of the 
investi gator, increases the risk of parti cipat ing in the study .
[18]have known or ongoing psychiatric disorders considered clinically significant 
by the investigator or demonstrate suicidal ideat ion on the Columbia Suicide 
Severit y Rating Scale (C -SSRS) .
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 24
LY573144[19]currently use, or within the past 1 y earused recreati onal drug s, or showed 
evidence of substance dependence within the past 6 months based on history  
at screening visit .
[20] s how evidence of human immunodeficiency  virus (HIV) infection and/or 
positive human HIV ant ibodies .
[
21] s how evidence of hepatit is C and/or positive hepat itis C ant ibody .
[
22] s how evidence of hepatit is B and/or positive hepat itis B surface antigen . 
[
23] are wom en with a posi tive pregnancy test or women who are l actating .
[24] intend to use over -the-counter or prescript ion medication, dietary  supplements 
within 14 days pri or to d osing and unt il study  discharge (apart from 
occasi onal acetaminophen or HRT) .
[25] h ave donated blood of more than 500 mL within 1 month prior to the 
screening visit. 
[
26] h ave an average weekly  alcoh ol intake that exceeds 21 units per week (males 
up to the age of 
65years ) and 14 units per week (females), or are unwilling to 
stop al coho l consumpt ion 48hours prior to dosing unt il the co mpletion of the 
study  (1 uni t = 12 oz or 360 m L of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 
mL o f distilled s pirits).
[27] have a clinically  significant abnorm ality in the neurol ogical  examinat ion.
[
28] have current or a history  of orthostati c hypotensi on (>20 -mmHg drop in 
systolic blood pressure, o r >10 -mmHg drop in diastolic blood pressure) with 
or wi thout di zziness and/or syncope at screening or admissio n to the CRU 
upon repeat testing
.
[29] are unwilling to refrain fro m tobacco -or nicotine -containing products while in 
the CRU or are unable to ab ide by CRU restrict ions.
[
30] have a n e stimated g lomerular filtration rate using Modificat ion of Diet in 
Renal Disease <60mL/min/1.73 m 2.
[31] have a history  of glauco ma.
[
32] have a history  of galactose intol erance, Lapp l actase deficiency ,or 
glucose -galactose m alabsorpti on.
[
33] in the opinio n of the invest igator or sponsor, are unsuitable for inclusio n in the 
study .
6.2.1. Rationale for Exclusion of Certain Study Candidates
Criteria [1] through [7] define a healt hy population suitable for evaluat ion in a Phase 1 study.  
Criteria [8] and [9] prevent conflict of interest in study  parti cipants.  Criteria [10] through [33] 
predominant ly exclude medical condit ions, m edicati on into lerance, and concomitant medicat ion 
use that m ay confound the assessment of study  endpoints.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 25
LY5731446.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects may undergo medical assessment sand review of compliance with 
requirements before continuing in the study .
6.3.1. Meals and Dietary Restrictions
On intensive PK sampling days (Days 1, 13, and 14), subjects will abstain fro m water 1 hour 
before and after dosing (except f or water given with the dose). Subjects will fast on these 
mornings for a minimum of 8 hours predose. Subjects will remain fast ing for 3 hours postdose, 
at whi ch time a m eal will be served.
Subjects m ay be permi tted to consum e a light breakfast at 1 hour postdose at the discret ion of the 
investigator on all other day s.
6.3.2. C affeine, Alcohol, and Tobacco
Caffeine –Subjects will refrain fro m consuming xanthine -or caffeine -containing food and 
drinks fro m 48 hours prior to admissio n, and while resident at the CRU.
Alcohol –Subjects will not consume alcoho l for 48 hours prior to dosing , and while resident at 
the CRU.
Tobacco –Subjects will refrain fro m using tobacco-or nicotine -containing products while 
resident at the CRU.
6.3.3. Activity
No strenuous exercise will be allowed for 48 hours prior to a dmissio n unt il after the fo llow-up 
visit.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) may  notbe 
re-screened .
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 26
LY5731447.Treatment
7.1. Treatment Administ ered
Table LAHT .2shows the treatment regimens for lasmiditan and topiramate.
Tablets of lasmiditan and topiramate will be administered orally wit h approximately 240mL o f 
room  temperature water in the morning of each dosing day in a sitt ing posit ion. Subjects will not 
be allowed to lie supine for 2hours after dosing, unless clinically indicated or for study  
procedures.
Table LAHT.2. Treatment sAdministered
Treatment NameLasmiditan
LY573144Lasmiditan Placebo Topiramate
Dosage Formulation Film-coated tablet Film-coated tablet Tablet
Unit Dose 
Strength(s)/Dosage 
Level(s)(1 200-mg) tablet/
200-mg lasmiditanNA (1 25-mg) tablet/
25-mg topiramate
(2 25-mg) tablet/
50-mg topiramate
Route of Administration Oral Oral Oral
Abbreviation:  NA = not applicable.
The dosing schedule is as fo llows:
Day 1: 1 oral  dose of l asmidi tan (1 × 200- mg tablet or placebo) in the morning
Two days fo llowing the init ial lasmiditan dose, s ubjects in the CRU will be administered the 
following topi ramate doses:
Day 
3:starting dose of a single 25-mg tablet
Days 4 to 7: 2 oral doses of a single 25-mgtabletseparated by  approximately 12 hours
Days 8to 13: 2 oral doses of50 m g (2 ×
25-mg tablets) each separated by  approximately 
12 hours
Day 14: Final topiramate dosing (2 × 25 -mg tablets) will be co -administered with 1 oral
dose of lasmiditan ( 1 × 200 -mgtablet or placebo) in the morning 
The invest igator or designee is responsible for
explaining the correct use of the IP(s) to the subject
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispens ationand collect ion
and returning all unused medicat ionsto Lilly  or its desi gnee at the end of the stud y
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 27
LY573144Note : In some cases, the CRU may destroy  the materi al if, during the invest igativesite 
select ion, the evaluator has verified and documented that the site has appropriate facilit ies and 
written procedures to dispose of clinical materials .
7.1.1. Packaging and Labeling
Each tablet of lasmiditan contains 200 mg of act ive ingredient and is provided as bulk supplies in 
bottles.
The study  site will  obtain topi ramate. 
The IPwill be labeled according to the country’s regulatory  requi rements .
7.2. Method of Treatment Assi gnment
The sponsor (or designee) will be responsible for generat ing each of the rando mizat ion schedules 
and distribut ing them direct ly to the CRU pharmacist.
7.2.1. Selection and Timing of Doses
Doses of topiramate will be administered at approxim ately  the same t imes on each dosing day 
(every  12 hours) except for Day  3and Day 14 when only 1 dose is administered .  On Day  14, 
topiramate (50 mg) shoul d be co -administered with lasmiditan (200 m g)
.The actual time of all 
dose administrations will be recorded in the subject ’s electronic case report form ( eCRF ).
7.3. Blinding
Invest igator and subject blinding of lasmiditan will be m aintained throughout the conduct of the 
study  as described in the separate Blinding Plan. Topi ramate will be administered open -label.
Emergency codes will be available to the pharmacy .  A code, which reveals the lasmiditan 
treatm ent group for a specific study  subject, m ay be opened during the study  only  if the subject’s 
well-being requires knowledge of the subject’s treatment assignment.
If a subject’s study  treatm ent assignment is unblinded, the subject must be discont inued from the 
study , unless the invest igator obtains specific approval fro m a Lilly clinical pharmaco logist or 
clinical research physician (CRP) for the study  parti cipant to contin ue in the study .  During the 
study , emergency  unblinding shoul d occur only by accessing the study  subject’s em ergency 
code.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a subject’s treatm ent assi gnment is warranted for m edical management of the event.  The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.  If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
promptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee.
7.4. Dose Modification
Dose m odificat ion will not be allowed during the study . 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 28
LY5731447.5. Preparation/Handl ing/Storage/Accountability
Only participants enro lled in the study  may receive IPor study materials, and only authorized 
CRU staff may  supply  or administer IP.All IPsshoul dbe stored in a nenvironmentally 
controlled and mo nitored (manual or automated) area in accordance with the labeled storage 
condi tions wi th access limited to the invest igator and authorized CRU staff.
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
7.6. Treatment Compliance
The IPwill be administered at the CRU , and documentati on of  treatm ent administrati on will 
occur at the CRU .
7.7. Concomitant Therapy
In general ,concomitant m edicat ion shoul d be avo ided;however ,acetaminophen (1 g, maximum  
4g/24 hours) may be administered at the discretion of the invest igator for treatment of headache ,
etc.  If the need for concomitant medicat ion (other than acetaminophen) arises, inclusi on or 
continuat ion of the subject may be at the discret ion of the invest igator after consultation wit h a 
Lilly clinical pharmaco logist orCRP .  Hormone repl acement the rapy is allowed per the inclusio n 
criteria. Any medicat ion used during the course of the study  must be documented.
7.8. Treatment after the End of the Study
Not applicable.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 29
LY5731448.Discontinuation Criteria
Subjects discont inuing fro m the study  prematurely for any  reason must com plete AEand 
follow-up procedures per Section 2of this protocol.
8.1. Discontinuation from Study Treatment
Discontinuati on of  the IPfor abnormal liver test result s should be considered by the investigator 
when a subject meets 1 of the following condi tions after consultation with the Lilly -designated 
medical mo nitor:
alanine aminotransferase ( ALT) ,aspartate aminotransferase (AST ) >5X upper limit of 
norm al (ULN )
ALT or AST > 3X ULN sustained for more than 2 weeks or
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN orinternat ional 
norm alized rati o>1.5 or
ALT or AST >3X ULN wit
h the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase (ALP ) >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5 ULN with the appearance of fatigue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) .
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ident ifies a pati ent who di d not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  clinical pharmacol ogist/CRP
and the invest igator to determine if the patient may continue in the study.  If both agree it i s 
medically appropriate to continue, the invest igator must obtain documented approval fro m the 
Lilly clinical pharmaco logist/CRP to allow the inadvertent ly enro lled patient to con tinue in the 
study  with or wi thout continued treatment with IP.
8.2. Discontinuati onfrom the Study
Subjects will be discont inued under the following ci rcumstances:
Enrollment in any other clinical study  involving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, r egulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the subject shoul d be discontinued from the study
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 30
LY573144oif the subject , for any  reason, requi res treatment with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
Subject Decisio n
othe subject ,or legal representative ,requests to be withdrawn from the study .
8.3. Subjects Lost to Follow -up
Asubject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the CRU .  Site personnel  are expected to m ake diligent 
attem pts to contact subjects who fail to return for a scheduled visit or were otherwise unable to 
be followed up by the site.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 31
LY5731449.Study Assessments and Procedures
Secti on 2 lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessm ents
This sect ion is not applicable for this study.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event ma y be 
considered an unant icipated benefit to the subject .
The invest igator is responsible for the appropriate medical care of subjects during the study .
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains resp onsible for fo llowing, through an appropriate healt
h care option, 
AEs that are serious or otherwise medically important, considered related to the IPor the study , 
or that caused the subject to discontinue the IPbefore complet ing the study .  The subject shoul d 
be followed unt il the event resolves, stabilizes with appropri ate di agnosti c evaluat ion, or i s 
reasonably  explained.  The frequency  of follow-up evaluat ions of the AE is left to the discret ion 
of the invest igator.
After the informed consent form ( ICF)is signed, CRU personnel will record, via eCRF ,the 
occurrence and nature of each subject ’s preexist ing conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study .  Addit ionally , site personnel will  
record any change in the condit ion(s) and the occurrence and nature of any  AEs.
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment , or a study procedure, taking into account the di sease, 
concomitant treatment ,or pathol ogies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the IPand/or study procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 32
LY573144If a subject ’s IP i s discont inued as a result of an AE, CRU personnel must report this to Lilly or 
its designee via eCRF .
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1 of the f ollowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience ( i.e., immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but m ay jeopardi zethe pati ent or may  requi re intervent ion to prevent 1 
of the other outcomes listed in the definit ion above.
Study  site personnel  must al ert the Lilly  CRP/ clinical pharmaco logist, or its desi gnee, of  any 
SAE as soon as pract ically possible.
Addit ionally , study site personnel  must al ert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin 24 hours of invest igator awareness o f the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all follow-up SAE information.
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting to the 
sponsor begins after the subject has signed informed consent and has received IP.  However, if 
an SAE occurs after signing informed c onsent, but prior to receiving IP, AND is considered 
Reasonably Possibly Related to a study  procedure then it MUST be reported .
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued from and/or com pleted the study  (the subject summary eCRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported followi ng the SAE 
process to collect data on the outcome for both mother and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to IPor procedure.  Lilly  has procedures that 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 33
LY573144will be fo llowed f or the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly co llects prod uct complaints on IPs and drug delivery  systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements.
Subjects shoul d be instructed to contact the invest igator as s oon as possible if he or she has a 
complaint or probl em wi th the IPso that the situation can be assessed.
9.3. Treatment of Overdose
9.3.1. Overdose of Lasmiditan
For the purposes of this study , an overdose of lasmidi tanis considered any dose higher than the 
dose as signed through randomizat ion.There is no specific ant idote for lasmiditan.  In the event 
of overdose, the subject should receive appropriate supportive care and AEs should be 
docum ented.
Refer to the I B.
9.3.2. Overdose of Topir amate
In the event of a topiramate overdose, the subject should receive appropriate supportive care 
according to the approved product label for advice on overdose.
Refer to the 2017 US Prescribing Information (Topi ramate US Prescribing Informat ion 
[https://www.topamax.co m/files/t opam ax.pdf]) . 
9.4. Safety
9.4.1. Laboratory Tests
For each subject , laboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).
9.4.2. Vital Si gns
For each subject , vital sign measurem ents shoul d be conducted according to the Schedule of 
Activities (Secti on
 2).
Blood pressure and pulse rate should be measured after at l east 5 minutes supine.  All supine 
blood pressure and pulse rate measurements will be done in triplicates at approximately  1-minut e 
intervals.  The l ast tri plicate vi tal sign can be used as the supine vital sign for the calculat ion of 
orthostati c changes.   Vital sign m easurements should be taken fro m the nondo minant and 
opposite arm as used for PK sampling, and for each individual su bject the same cuff size should 
be used throughout the study  for measurements of blood pressure.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 34
LY573144Where orthostati c measurements are required, subjects shoul d be supine for at least 5 minutes 
and stand for at least 2minutes.
If the subject feels unable to stand, supine vital signs only will be recorded. 
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  Addit ional vital signs may be m easured during each study  periodif 
warranted.
9.4.3. Electrocardiograms
For each subject , ECGs should be collected according to the Schedule of Activit ies (Secti on 2) .
Any clinically  significant findings fro m ECGs that resul t in a di agnosis and that occur after the 
subject receives the first dose of the IP,shoul d be reported to Lilly ,or its desi gnee ,as an AE via 
eCRF . 
For each subject , a single 12-lead digital ECG will be collected according to the Schedule of 
Activities.  
Electrocardi ogram s must be recorded before collecting any  blood s amples.  Subjects
must be supine for approximately 5 to 10 minutes before ECG collect ion and remain supine but 
awake during ECG collect ion.  Electrocardi ograms may  be obtained at addit ional times, when 
deem ed clinically  necessary .  All ECGs recorded should be stored at the invest igational site.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
design ee) at the si te as soon after the time of ECG collect ion as possible, and ideally while the 
subject is still present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically relevant findings be 
ident ified.  
If a clinically significant finding is ident ified (including, but not limited to ,changes in QT/QTc 
interval  from baseline) after enrollment, the investigator will determine if the subject can 
continue in the study .  The invest igator ,or qualified designee ,is responsible for determining if 
any change in subject management i s needed ,and must document his/her review of the ECG 
printed at the time of collection.  Any new clinically relevant finding should be reported as an
AE.
9.4.4. C olumbia Suicide Severity Rating Scale
The C -SSRS (Posner 2007; Posner et al. 2007a,b) captures the occurrence, severit y, and 
frequency  of suicide -related thoughts and behaviors during the assessment period. The C -SSRS 
and a corresponding Self -Harm  Supplement Form  will be administered according to the 
Schedule of Activities by appropriately trained site personnel. Any significant change would 
need to be referred to a psy chiatri st.
If the invest igator determines that sui cide-related behaviors have occurred, the Lilly self -harm
follow-up form  will be used to collect additional informat ion to allow for a more complete
assessment of these behaviors. As noted above, subjects with any clinically significant change,
as determi ned by  the invest igator, will be referred to a psy chiatrist.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 35
LY5731449.4.5. Neurological Examinations
Neurol ogical examinat ions will be performed as indicated in the Schedule of Act ivities. 
The neuro logical examinat ion will include observation for tremors and testing of ocular 
movements, finger -to-nose and heel -to-shin testing, rapid alternat ing movements, tandem 
walking, strength testing ,and muscle stretch (deep) reflexes.  An experienced clinician will 
conduct the neurological examinat ion.  Pl ease see Appendix 6 for a descript ion of the techniques 
used.
Positive significant findings (such as nystagmus, dystaxia, ataxia, irregular alternating 
movements, and hyperr eflexia) on neuro logical examinat ion of ocul omotor testing, tandem 
walking, heel -to-shin, rapid alternat ing movements, finger -nose coordinat ion, and muscle stretch 
(deep) reflexes will be recorded as preexisting condit ions or AEs.  A clinically significant change 
from baseline or clinically significant new findings should be a considerat ion for discont inuat ion 
of study  drug.
9.4.6. Safety Monitoring
The Lilly clinical pharmaco logist or CRP /scientist will mo nitor safety  data throughout the course 
of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly clinical 
pharmaco logist or CRP will periodically  review the following data:
trends in safety  data
laboratory  analy tes 
AEs 
When appropriate, the Lilly clinical pharmaco logist or CRP will consult wit h the funct ionally 
independent Global Pat ient Safety  therapeut ic area physician or clinical research scient ist.
9.4.6.1. Hepatic Safety
If a study  subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or el evated TBL ≥2X 
ULN, liver tests 
(Appendix 4 ) shoul d be repeated wi thin 3 to5 day s including ALT, AST, ALP, 
TBL, direct bilirubin , gamma -glutamyl transferase, and creatinine kinase to confirm the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator based on 
consultation wit h the Lilly clinical pharmaco logist or CRP .  Monitoring should continue unt il 
levels norm alize and/or are return ingto approximate baseline levels. 
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥5X ULN on 2or more consecutive blood tests
elevation ofserum  TBL to ≥2X ULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALP to ≥2X ULN on 2or more consecutive blood tests 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 36
LY573144patient/subject di scontinued from treatment due to a hepat ic event or abnormalit y 
of liver tests
hepatic event considered to be a SAE.
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities, venous blood samples o f 
approximately  3mL each will be co llected to determine the plasma concentrations of lasmidi tan
and its metabolites .  Similarly, at times s pecified in the Schedule of Act ivities, 2mL of venous 
blood sam ples will  be collected to determine the plasma concentrations of topiramate. A 
maximum o f 3samples may be collected at addit ional time po ints during the study  if warranted 
and agreed upon between both the invest igator and sponsor.  Instructions for the collect ion and 
handling of blood samples will be provided by  the sponsor .  The actual date and time (24-hour 
clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor.
Concentrations of lasmidi tan and its metabo lites will be assayed using a validated liquid 
chromatography  tandem -mass spectrometry  (LC-MS/MS )method.  Analyses of samples 
collected from subjects who received placebo are not planned.
Concentrations of topiramate will be assayed using a validated LC-MS/MS method.  
Bioanaly tical samples collected to m easure IP concentrations will be retained for a maximum o f 
2 yearsfollowing l ast subject visit for the study .  During this t ime, samples remaining after the 
bioanalyses may  be used for expl oratory  analyses.
9.6. Pharmacodynamic s
Not applicable.
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities, where l ocal regulati ons all ow.
Samples willnot be used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
lasmiditan or topi ramate and to invest igate genetic variants thought to play a role in migraine .  
Assessment of variable response may  include evalua tion of  AEs or differences in efficacy.
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by the invest igativesite personnel .
Samples will  be retained for a m aximum  of 15 y ears after the l ast subject visit, or for a shorter 
period if local regulat ionsand/or ERBs impose shorter time limits , for the study  at a f acilit y 
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 37
LY573144selected by Lilly or i ts desi gnee .  This retenti on peri od enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the devel opment of lasmiditan or after lasmidi tanis commercially available.  
Molecu lar techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, e xisting approaches include who le geno me or exome 
sequencing, geno me-wide associ ation studies, multiplex assays, and candidate gene studies.  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion. 
9.8. Biomarker s
Not a pplicable.
9.9. Health Economics
Thissection is not applicable for this study.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 38
LY57314410. Statistical Considerat ions and Data Analysis
10.1. Sample Size Determination
Approximately  30subjects will be enro lled, so that at least21subjects complete the study.   
Subjects will be rando mized in a 2:1 ratio of lasmidi tan 200 m g:placebo.   The sample size is 
custom ary for Phase 1 studies evaluat ing safet y and tolerabili ty, and is not powered on the basis 
of stati stical hypothesis testing.
Subjects who are randomized but who do not complete Day 14treatm ent m ay be repl aced to 
ensure that enough subjects complete the study .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f subject disposit ion will be provided at the end of the study . 
10.2.2. Study Participant Characteristics
The subjects’ age, sex, weight, height, BMI, race, and other demographic chara cterist ics will be 
recorded and summarized .
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee .
Pharmacokinet icanalyses will be conducted on data fro m all subjects who receiv eat least 1 dose 
of lasmiditan or topiramate and have evaluable PK .  
Safety analyses will be conducted for all enro lled subjects , whether or not they  com pleted all  
protocol  requi rements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the resul ts of other studies for populat ion PK analysis purposes to 
avoid issues with post hoc analyses and inco mplete di sclosures of ana lyses.  
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed, and if the frequency o f events allows, safet y 
data will be summarized using descript ive methodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with IPas perceived by the invest igator.  Symptoms reported to occur prior to enrollment will be 
distinguished from those reported as new or increased in severit y during the study .  Each 
symptom  will be classifi ed by  the m ost sui table term fro m themedical regulatory  dictionary.
The number of IP-related SAEs will be reported.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 39
LY57314410.3.1.2. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  laboratory parameters, vi tal signs,
neuro logical examinati ons, and C -SSRS .  The parameters will be listed, and summarized using 
standard descript ive statist ics.  Addi tional analysis will be performed if warranted upon review 
of the data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmac okinet ic parameter estimates for lasmiditan and its metabolites,and topi ramate will be 
calculated using standard nonco mpartmental methods of analysis and summari zed using 
descript ive statistics .
The primary  parameters for analysis will be C max, tmax,AUC( 0-tlast) and AUC from zero to 
infinit yfor lasmiditan and its metabo liteson Days 1 and 14,and C max, tmax, and AUC during 1 
dosing interval for topi ramate on Day s 13and 14.  Other noncompartmental parameters, such as 
half-life, apparent clearance, and apparent volume of distribut ion may be reported.
10.3.2.2. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameter swill be eval uated to determine the impact of top iramate 
co-administrati on on the PK of a single dose of lasmiditan and its metabo lites.  Log -transformed 
Cmaxand AUC parameters will be evaluated in a linear mixed -effects m odel with fixed effects for 
treatm ent (l asmidi tan co -administered with topir amate [Day  14; test treatm ent] versus lasmiditan 
alone [Day 1; ref erence treatm ent]) , and a random effect for subject .  The treatment differences 
will be back -transformed to present the ratios of geometric means and the corresponding 90% 
confidence interval ( CI)
.
A similar analysis will be performed to determine the impact of co -administration of a single 
dose of lasmiditan on the steady -state PK of topiramate.  The model will include the fo llowing 
treatm ents:  topi ramate co -administered with lasmiditan (Day 14; test treatme nt) versus 
topiramate al one (Day 13; reference treatment).
The t maxwill be analyzed using the Wilco xon signed rank test.  Estimates of th e median 
difference based on th e observed medians, 90% CIs,and p -values fro m the Wilcoxon test will be 
calculated.
Addit ional analyses m ay be performed, as warranted.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 40
LY57314411. References
Bialer M, Shekh -Ahmad T, Braun T, Halorsen M. Comparat ive steady -state pharmacokinet ic 
evaluat ion of immediate -release topiramate and USL255, a once -daily  extended- release 
topiramate form ulation. Epilepsia . 2013;54(8):144 4-1452.
Manitpisitkul P, Curti n CR, Shalayda K, Wang S, Ford L, Heald D. Pharmacokinet ic interact ions 
between topiramate and dilt iazem, hydrochlorothiazide, or propranolo l. Clin Pharmacol Drug 
Dev. 2014 a;3(5):378 -
387.
Manitpisitkul P, Curti n CR, Shalayda K, Wang S, Ford L, Heald D. Pharmacokinet ic interact ions 
between topiramate and pioglitazone and met formin. Epilepsy Res . 2014 b;108(9):1519 -
1532.
Posner K
.State of the science: measurement of suicidal adverse events and the Co lumbia suicide 
severi ty rating scale. Boca Raton, FL: NCDEU; 2007.
Posner K, Melvin GA, Stanley B, Oquendo MA, Gould M. Factors in the assessment of 
suicidality in youth. CNS Spectr . 2007a;12(2) :156-162.
Posner K, Oquendo MA, Gould M, Stanley B, Davie s M. Col umbia Classificat ion Algorithm o f 
Suicide Assessment (C -CASA): classificat ion of sui cidal events in the FDA’s pediatric 
suicidal risk analysis of ant idepressants. Am J Psychiatry . 2007b;165 (7):1035 -1043.
Topiramate US Prescribing Information resour ce page. Topomax web site. May 2017. Available 
at: https://www.topamax.co m/files/topamax.pdf .Accessed June 15, 2017.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 41
LY573144Appendix 1. Abbreviations and Definitions
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 42
LY573144Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally a ssociated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
BMI body mass index
CI confidence interval
Cmax maximum observed drug concentration
CNS central nervous system
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality , purity , durability , reliability , safety  or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requ irements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be re -tested at some defined time point, depending on the steps required to obtain 
confirmed results.
CRP clinical research physician:  Individual responsible for the medical conduct of the stu dy.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician ,or other medical officer.
CRU clinical research unit
C-SS RS Columbia Suicide Severity Rating Scale
CYP cytochrome P450
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 43
LY573144enter Subjects entered into a study are those who sign the i nformed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
GCP good clinical practice
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study , after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate. Informed consent is documented by means of a 
written, signed, and dated informed consent form .  
investigational 
product (IP)Apharmaceutical form of an active ingredient or placebo being test ed or used as a reference 
in a clinical study, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
LC-MS/MS liquid chromatography tandem -mass spectrometry
legal 
representativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject , to the subject’s participation in the clinical study.
non-
investigational 
product (non -IP)A product that is not being tested or used as a reference in the clinical study, but is provided 
to subjects and used in accordance with the protocol, such as concomitant or rescue/escape 
medication for preventative, diagnostic, or therapeutic reasons, medication to ensure 
adequate medical care, and/or products used to induce a physiological response.
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PK pharmacokinetic(s)
QTc corrected QT interval
randomize The process of assigning subjects/ patients to an experimental group on a random basis .
SAE serious adverse event
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 44
LY573144screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
SUSAR suspected unexpected serious adverse reaction
TBL total bilirubin level
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship w ith this 
treatment 
tmax time of maximum observed drug concentration
ULN upper limit of normal
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 45
LY573144Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Total CO 2
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC) Gluco se (random)
Platelets Blood urea nitrogen (BUN)
Differential WBC absolute counts and % of Total protein
Neutrophils Albumin
Lymphocy tes Reflex total bilirubin
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Creatinine
Gamma -glutamyl transferase (GGT)
Urinalysis
Specific gravity
pH
Protein
Glucose Ethanol testing b
Ketones Urine drug screen b
Urine pregnancy test
Bilirubin Hepatitis B surface antigen a
Urobilinogen Hepatitis C antibody a
Blood HIV a
Nitrite Serum pregnancy test (females only) a
Urine microscopic (if positive result for blood) FSH (females only, if applicable) c
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cell; 
WBC = white blood cell.
aPerformed at screening only .
bUrine drug screen and ethanol level willbe performed locally at screening and may be repeated prior to 
admission to the clinical research unit and at other times indicated in the Schedule of Activities (Section 2).  
cPerformed at screening only, for confirmation of postmenopausal status.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 46
LY573144Appendix 3. Study  Governance, Regulatory ,and Ethical 
Considerations
Informed Consent
The invest igator is responsible for
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  Thi s
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of IP.
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any new inform ation that m ay be relevant to the subject’ swillingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Ethical Review
The invest igator or appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by  Internat ional Council for Harmonisat ion (ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval o f the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol  and wi th
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences Internat ional Ethical Guidelines 
2)applicable ICH GCP Guidelines
3)applicable laws and regulations
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 47
LY573144Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study .
Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the CRU , as appropri ate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRF s, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in conta ct with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collect ion.
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator wil l keep records of all original source data.  This might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the o riginal  source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into
the data capture system.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 48
LY573144Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.
The p urpose and use of subject/patient personal information co llected will be provided in a 
written docum ent to the subject/patient by  the sponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its designee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 49
LY573144Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatmen t-emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with Lilly or i ts desi gnee CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear Antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CPKAnti -smooth Muscle Antibody (or Anti-actin 
Antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 50
LY573144Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sampling ( screening, safet y laboratori es, and bioanaly tical assays) during the study .
Protocol H8H -MC -LAHT Sampling Summary
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (m L)
Screening tests a 45 1 45
Clinical laboratory tests a 12.5 5 62.5
Lasmiditan and metabolite 
pharmacokinetics b3 27 81
Topiramate pharmacokinetics b 2 20 40
Pharmacogenetics 10 1 10
Total 238.5
Total for clinical purposes rounded up to the nearest 10 mL 240
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 51
LY573144Appendix 6. Neurological Examinations
Tests for Dysfunction on Neurological Examination
Abnormality Method of Examination
Gait dy staxia Free walking for broad -based gait
Tandem walking
Nystagmus Have patient follow your finger through fields of gaze
Irregular alternating movements Thigh slapping test
Arm dy staxia Finger -to-nose
Leg dy staxia Heel-to-shin
Scapular winging Strength testing
Hyperreflexia Muscle stretch (deep) reflexes
Dystaxia = incoordination of intentional movements
Neurological Examination
1) Test station (stance) and gait:
Inspect the patient for swaying when standing and for dy staxia o f gait.
Ask the pati ent to stand with feet together.
Ask the pati ent to take 6 steps along a straight line, walking heel to toe (tandem 
walking).
2) Test ey e movements:
Observe spontaneous ey e movements.
Observe the patient’s eyes as they pursue the examiner’s finger as it moves fro m 
side-to-side and up and down through the full range of ocular movements.
3) Test rapid alternat ing movements:
Thigh-slapping test.  Test each hand separately.
Dem onstrate the acti on to the patient by  lightly  slapping y our own thi gh, 
alternat ing first wi th the palm and then wit h the back of the hand as rapidly and 
rhythmically as possible, making an audible sound with each slap.
Instruct the patient to make act ions that sound exactly like yours.
4) Test arm movement:
Finger -to-nose test.  Ask the patient to extend his arms out in front.
Instruct him to place his index finger on the tip of his nose by  moving his finger 
in slowly , and pl acing the ti p of his finger exact ly on the ti p of his nose, trying not 
to miss.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 52
LY573144Inspect for intention tremor of the movement i n progress, and the precisio n with 
which the patient touches the tip of his nose.
If uncertain of the result, have the patient alternat ively touch his nose, y our finger, 
and his nose several times.
5) Test leg movement:
Heel-to-shin test.  The patient is s itting or supine.
Instruct the patient to place one heel precisely  on the opposi te knee and run the 
heel in a straight line precisely down the shin.
6) Strength testing:
Shoul der gi rdle.  Try  to press the pati ent’s arms down after he or she abducts
them toshoulder height.  Look for scapular winging.
Upper extremit ies.  Test the biceps, triceps, wrist dorsiflexors, and grip.  Test 
strength of finger abduct ion and extension.
Lower extremit ies.  Test hip flexors, abductors and adductors, knee flexors, foot 
dorsiflexors, invertors, and evertors.  Have patient do a deep knee bend to test 
knee extension.
Grade strength on a 0 to 5 scale.
7) Muscle stretch (deep) reflexes:
Biceps
Triceps
Quadri ceps (knee reflex)
Triceps surae (ankle jerk)
Grade 0 to 4+
Positive significant findings (such as nystagmus, dystaxia, ataxia, and irregular alternat ing 
movements*) on neurological examinat ion of oculomotor testing, tandem walking, heel -to-shin, 
rapid alternat ing movements, finger -nose coordination and muscle stretch (deep) reflexes will be 
recorded as pre -existing condit ions or adverse events.  Increase in severit y from baseline or new 
findings should be a considerat ion for discontinuatio n of study  drug.
* Enter “clumsiness” for irregular alternat ing movements on the eCRF as the pre -exist ing 
condi tion or adverse event.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 53
LY573144Appendix 7. Protocol A mendment H8H-MC-LAHT(c) 
Summary  Safety , Tolerability , and Pharmacokinetics of 
Lasmiditan when Co -administered with Topiramate in 
Healthy  Subjects
Overview
Protocol  H8H -MC-LAHT, Safet y, Tolerabilit y, and Pharmacokinet ics of Lasmiditan when Co -
administered with Topiramate in Healt hy Subjects ,has been amended.  The new protocol is 
indicated by  Amendment ( c) and will be used to conduct the study in place of any preceding 
versio n ofthe protocol .
Following feedback from the FDA from the Type C m eeting on 12 October 2017, the protocol 
was amended to include an assessment on l asmidi tan metabo lites.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 54
LY573144Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
1. Protocol Synopsis
Statistical Analysis:
Safety parameters that will be assessed include safety laborator y parameters, vital signs, neurological examination, 
Columbia Suicide Severity Rating Scale , and 12-lead electrocardiogram parameters.  The parameters will be listed, 
and summarized using standard descriptive statistics , as appropriate .  
Pharmacokinetic parameter estimates for lasmiditan , its metabolites ,and topiramate will be calc ulated using
standard no ncompartmental methods of analysis.   The parameters will be listed, and summarized using standard 
descriptive statistics , as appropriate .
Pharmacokinetic parameters will be evaluated to determine the impact of topiramate co -administ ration on the PK of 
a single dose of lasmiditan and its metabolites .  Log -transformed C maxand area under the concentration versus time 
curve parameters will be evaluated in a linear mixed -effects model with fixed effects for treatment (lasmiditan co -
admin istered with topiramate [Day 14; test treatment] versus lasmiditan alone [Day 1; reference treatment]), and a 
random effect for subject.  The treatment differences will be back -transformed to present the ratios of geometric 
means and the corresponding 90% confidence interval (CI).
A similar analysis will be performed to determine the impact of co -administratio n of a single dose of lasmiditan on 
the steady -state PK of topiramate.  The model will include the following treatments:  topiramate co -administered 
with lasmiditan (Day 14; test treatment) versus topiramate alone (Day 13; reference treatment).
The t maxwill be analyzed using the Wilcoxon signed rank test.  Estimates of the median difference based on the 
observed medians, 90% CIs, and p -values from the Wilcoxon test will be calculated.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 55
LY5731442. Schedule of A ctivit ies
Study Schedule Protocol H8H -MC-LAHT
Scree ning Study Days Discharg
eFollow -
up/EDComments
Procedure -28 to -2 
days 
prior to 
Day 1-1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day 16 ~10 
days 
after 
last dose
Lasmiditan and 
Metabolite PK 
SamplesPredose, 
0.5, 1, 
1.5, 2, 3, 
4, 6, 8, 
12h24, 
36
h48
hPredose, 
0.5, 1, 
1.5, 2, 
2.5, 3, 
4, 6, 8, 
12h24, 
36h48h
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 56
LY5731444. Objectives and Endpoints
Table LAHT. 1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the safety and tolerability of a single dose 
of lasmiditan in combination with topiramate in healthy 
subjects. A summary of the number of treatment -emergent 
adverse events and serious adverse events
Secondary
To evaluate the pharmacokinetics of lasmiditan alone 
and in combination with topiramate in healthy subjects.
To evaluate the pharmacokinetics of topiramate alone 
and in combination with lasmiditan .Cmax, tmax, AUC(0 -tlast) and AUC(0 -∞)
Cmax, tmax, and AUC 
Exploratory
To evaluate the pharmacokinetics of lasmiditan 
metabolites alone and in combination with topiramate 
in healthy  subjects.Cmax, tmax, AUC(0 -tlast) ,and AUC(0 -∞)
Abbreviations:  AUC(0 -tlast) = area under the concentration versus time curve from time zero to time t, where t is 
the last time point with a measurable concentration; AUC(0 -∞)= area under the concentration versus time curve
from zero to infinity; AUC= area under the concentration versus time curve during 1 dosing interval; Cmax= 
maximum observed drug concentration ; tmax= time to Cmax.
5.1. Overall Design
This is a Phase 1 ,parallel, placebo -controlled, fixed -sequence study  with open -label 
administration of topiramate and invest igator -and subject -blind administration of 
lasmiditan/placebo conducted in healthy subjects.
Subjects will be admitted to the CRU on Day  -1 and are expected to remain a resident until all 
assessments are completed on Day  16;however ,subjects m ay be allowed to leave the CRU at 
the discret ion of the invest igator. 
Study  governance considerations are described in detail in Appendix 3 .
Lasmiditan and topiramate doses will be administered at the CRU. Subjects will be rando mly 
assigned in a 2:1 ratio to receive lasmiditan or placebo on both lasmiditan dosing days (Days 1 
and 14).  A single oral dose of study  drug (200 -mg lasmiditan or pla cebo) will be administered in 
the morning on Day 1.  After l asmidi tan wash -out, topi ramate will be titrated up to 100 mg on 
Days 3 to 13.  On Day  14, 1 oral dose of l asmidi tan 200 m gor placebo will be co -administered
with the final topiramate dose (50 mg) in the morning.
Blood sam pling for PK assessment will be conducted predose and at time points up to 48 hours 
postdose on Days 1 and 14 for the measurement of plasma concentrations of lasmiditan and i
ts 
metabo lites.  Blood sam ples will  also be collected pr edose and up to 12 hours postdose on Day s 
13 and 14 for the measurement of plasma concentrations o f topiramate.
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 57
LY573144A follow-up visit will take place at least 10 days following co -administration of lasmiditan and 
topiramate (Day  14).
9.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities, venous blood samples o f 
approximately  3mL each will be co llected to determine the plasma concentrations of lasmiditan
and itsmetabolite s.  Similarly, at times specified in the Schedule of Act ivities, 2 m L of venous 
blood sam ples will  be collected to determine the plasma concentrations of topiramate.  A 
maximum o f 3 sam ples m ay be collected at addit ional time po ints during the study  if warranted 
and agreed upon between both the invest igator and s ponsor.  Instructions for the collect ion and 
handling of blood samples will be provided by  the sponsor .  The actual date and time (24 -hour 
clock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved b y the sponsor and stored at a facilit y 
designated by  the sponsor.
Concentrations of lasmiditan and its metabo liteswill be assayed using a validated liquid 
chromatography  tandem -mass spectrometry  (LC-MS/MS) method.  Analyses of samples 
collected from subje cts who received placebo are not planned. 
Concentrations of topiramate will be assayed using a validated LC -MS/MS m ethod.  
Bioanaly tical samples collected to m easure IP concentrations will be retained for a maximum o f 
2 years fo llowing l ast subject visit for the study .  During thi s time, samples remaining after the 
bioanalyses may  be used for expl oratory  analyses.
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for lasmiditan and i ts metabo lites,and topi ramate will be 
calculated using standard noncompartmental methods of analysis and summarized using 
descript ive statistics.
The primary  parameters for analysis will be C max, tmax, AUC(0 -tlast) and AUC from  zero to 
infinit y for lasmiditan and its metabo liteson Days 1 and 14, and C max, tmax, and AUC during 1 
dosing interval for topiramate on Day s 13 and 14.  Other noncompartmental parameters, such as 
half-life, apparent clearance, and apparent volume of distribut ion may be reported.
10.3.2.2. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameters will be evaluated to determine the impact of topiramate 
co-administration on the PK of a single dose of lasmiditan and its metabo lites.  Log -transformed 
Cmaxand AUC parameters will be evaluated in a linear mixed -effects m odel with fixed effects for 
treatm ent (l asmidi tan co -administered with topiramate [Day  14; test treatment] versus lasmiditan 
alone [Day 1; ref erence treatm ent]), and a random effect for subject.  The treatment differences 
will be back -transf ormed to present the ratios of geometric means and the corresponding 90% 
confidence interval (CI).
H8H-MC-LAHT(c) C linical Pharmacology Protocol Page 58
LY573144Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sampling ( screening, safet y laboratori es, and bioanaly tical assays) during the study .
Protocol H8H -MC -LAHT Sampling Summary
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (mL)
Screening tests a 45 1 45
Clinical laboratory tests a 12.5 5 62.5
Lasmiditan and metabolite
pharmacokinetics b3 27 81
Topiramate pharmacokinetics b 2 20 40
Pharmacogenetics 10 1 10
Total 238.5
Total for clinical purposes rounded up to the nearest 10 mL 240
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional samples.
Leo Document ID = 9147c1ba-6644-46bd-a6c6-a9340b641595
Approver: 
Approval Date & Time: 19-Oct-2017 17:11:26 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 20-Oct-2017 08:36:56 GMT
Signature meaning: Approved
PPD
PPD